What's breaking now, across thousands of outlets.
Employers are expecting a median 9.2% increase in medical spending next year, according to a new survey. But they’ve underestimated actual cost growth for the past three years, so even that figure may be too optimistic.
We haven't written up this one. Healthcare Dive has the full story — the link below goes straight to it.
Rasonque joins a short list of treatment options for one of the country’s deadliest types of cancer.
The Sam Altman-backed longevity biotech company is upping the dose of its experimental Alzheimer's drug in clinical trials.
The drug is a once-daily pill designed to block several forms of the RAS protein, which helps drive tumor growth in many pancreatic cancers.
A surprising connection emerged in a major study, raising new questions about whether one routine shot could protect the brain.
Pancreatic cancer is considered one of the hardest to treat and most serious cancers
